Ardelyx, Inc. (ARDX)
NGM · Healthcare · Biotechnology
$5.69
-1.73%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.41B
Shares Outstanding
247.0M
P/S (TTM)
3.3x
Exchange
NGM
Currency
USD
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 97.7M | 110.3M | 125.2M | 94.5M |
| Gross Profit | 85.3M | 106.3M | 114.4M | 89.7M |
| Operating Income | -14.4M | 4.7M | 5.1M | -32.8M |
| Net Income | -19.1M | -969K | -407K | -37.6M |
| Diluted EPS | $-0.08 | $0.00 | $0.00 | $-0.15 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 52.2M | 124.5M | 333.6M | 407.3M |
| Gross Profit | 48.0M | 106.7M | 283.1M | 367.8M |
| Operating Income | -63.8M | -63.3M | -27.9M | -41.0M |
| Net Income | -67.2M | -66.1M | -39.1M | -61.6M |
| Diluted EPS | $-0.42 | $-0.30 | $-0.17 | $-0.26 |